1mfp
From Proteopedia
(New page: 200px<br /><applet load="1mfp" size="450" color="white" frame="true" align="right" spinBox="true" caption="1mfp, resolution 2.33Å" /> '''E. coli Enoyl Reduct...) |
|||
| Line 1: | Line 1: | ||
| - | [[Image:1mfp.gif|left|200px]]<br /><applet load="1mfp" size=" | + | [[Image:1mfp.gif|left|200px]]<br /><applet load="1mfp" size="350" color="white" frame="true" align="right" spinBox="true" |
caption="1mfp, resolution 2.33Å" /> | caption="1mfp, resolution 2.33Å" /> | ||
'''E. coli Enoyl Reductase in complex with NAD and SB611113'''<br /> | '''E. coli Enoyl Reductase in complex with NAD and SB611113'''<br /> | ||
==Overview== | ==Overview== | ||
| - | Bacterial enoyl-ACP reductase (FabI) is responsible for catalyzing the | + | Bacterial enoyl-ACP reductase (FabI) is responsible for catalyzing the final step of bacterial fatty acid biosynthesis and is an attractive target for the development of novel antibacterial agents. Previously we reported the development of FabI inhibitor 4 with narrow spectrum antimicrobial activity and in vivo efficacy against Staphylococcus aureus via intraperitoneal (ip) administration. Through iterative medicinal chemistry aided by X-ray crystal structure analysis, a new series of inhibitors has been developed with greatly increased potency against FabI-containing organisms. Several of these new inhibitors have potent antibacterial activity against multidrug resistant strains of S. aureus, and compound 30 demonstrates exceptional oral (po) in vivo efficacy in a S. aureus infection model in rats. While optimizing FabI inhibitory activity, compounds 29 and 30 were identified as having low micromolar FabK inhibitory activity, thereby increasing the antimicrobial spectrum of these compounds to include the FabK-containing pathogens Streptococcus pneumoniae and Enterococcus faecalis. The results described herein support the hypothesis that bacterial enoyl-ACP reductases are valid targets for antibacterial agents. |
==About this Structure== | ==About this Structure== | ||
| - | 1MFP is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Escherichia_coli Escherichia coli] with SO4, NAD and IDN as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Enoyl-[acyl-carrier-protein]_reductase_(NADH) Enoyl-[acyl-carrier-protein] reductase (NADH)], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=1.3.1.9 1.3.1.9] Full crystallographic information is available from [http:// | + | 1MFP is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Escherichia_coli Escherichia coli] with <scene name='pdbligand=SO4:'>SO4</scene>, <scene name='pdbligand=NAD:'>NAD</scene> and <scene name='pdbligand=IDN:'>IDN</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Enoyl-[acyl-carrier-protein]_reductase_(NADH) Enoyl-[acyl-carrier-protein] reductase (NADH)], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=1.3.1.9 1.3.1.9] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1MFP OCA]. |
==Reference== | ==Reference== | ||
| Line 14: | Line 14: | ||
[[Category: Escherichia coli]] | [[Category: Escherichia coli]] | ||
[[Category: Single protein]] | [[Category: Single protein]] | ||
| - | [[Category: Burgess, W | + | [[Category: Burgess, W J.]] |
| - | [[Category: Elkins, P | + | [[Category: Elkins, P A.]] |
| - | [[Category: Head, M | + | [[Category: Head, M S.]] |
| - | [[Category: Huffman, W | + | [[Category: Huffman, W F.]] |
| - | [[Category: Jakas, D | + | [[Category: Jakas, D R.]] |
| - | [[Category: Janson, C | + | [[Category: Janson, C A.]] |
| - | [[Category: Jr., W | + | [[Category: Jr., W E.DeWolf.]] |
| - | [[Category: Keller, P | + | [[Category: Keller, P M.]] |
| - | [[Category: Manley, P | + | [[Category: Manley, P J.]] |
| - | [[Category: Miller, W | + | [[Category: Miller, W H.]] |
| - | [[Category: Moore, T | + | [[Category: Moore, T D.]] |
| - | [[Category: Newlander, K | + | [[Category: Newlander, K A.]] |
| - | [[Category: Payne, D | + | [[Category: Payne, D J.]] |
[[Category: Pearson, S.]] | [[Category: Pearson, S.]] | ||
| - | [[Category: Polizzi, B | + | [[Category: Polizzi, B J.]] |
[[Category: Qiu, X.]] | [[Category: Qiu, X.]] | ||
| - | [[Category: Rittenhouse, S | + | [[Category: Rittenhouse, S F.]] |
| - | [[Category: Seefeld, M | + | [[Category: Seefeld, M A.]] |
| - | [[Category: Uzinskas, I | + | [[Category: Uzinskas, I N.]] |
| - | [[Category: Wallis, N | + | [[Category: Wallis, N G.]] |
[[Category: IDN]] | [[Category: IDN]] | ||
[[Category: NAD]] | [[Category: NAD]] | ||
| Line 41: | Line 41: | ||
[[Category: fabi]] | [[Category: fabi]] | ||
| - | ''Page seeded by [http:// | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 13:54:47 2008'' |
Revision as of 11:54, 21 February 2008
|
E. coli Enoyl Reductase in complex with NAD and SB611113
Overview
Bacterial enoyl-ACP reductase (FabI) is responsible for catalyzing the final step of bacterial fatty acid biosynthesis and is an attractive target for the development of novel antibacterial agents. Previously we reported the development of FabI inhibitor 4 with narrow spectrum antimicrobial activity and in vivo efficacy against Staphylococcus aureus via intraperitoneal (ip) administration. Through iterative medicinal chemistry aided by X-ray crystal structure analysis, a new series of inhibitors has been developed with greatly increased potency against FabI-containing organisms. Several of these new inhibitors have potent antibacterial activity against multidrug resistant strains of S. aureus, and compound 30 demonstrates exceptional oral (po) in vivo efficacy in a S. aureus infection model in rats. While optimizing FabI inhibitory activity, compounds 29 and 30 were identified as having low micromolar FabK inhibitory activity, thereby increasing the antimicrobial spectrum of these compounds to include the FabK-containing pathogens Streptococcus pneumoniae and Enterococcus faecalis. The results described herein support the hypothesis that bacterial enoyl-ACP reductases are valid targets for antibacterial agents.
About this Structure
1MFP is a Single protein structure of sequence from Escherichia coli with , and as ligands. Active as [acyl-carrier-protein_reductase_(NADH) Enoyl-[acyl-carrier-protein] reductase (NADH)], with EC number 1.3.1.9 Full crystallographic information is available from OCA.
Reference
Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK., Seefeld MA, Miller WH, Newlander KA, Burgess WJ, DeWolf WE Jr, Elkins PA, Head MS, Jakas DR, Janson CA, Keller PM, Manley PJ, Moore TD, Payne DJ, Pearson S, Polizzi BJ, Qiu X, Rittenhouse SF, Uzinskas IN, Wallis NG, Huffman WF, J Med Chem. 2003 Apr 24;46(9):1627-35. PMID:12699381 [[Category: Enoyl-[acyl-carrier-protein] reductase (NADH)]]
Page seeded by OCA on Thu Feb 21 13:54:47 2008
Categories: Escherichia coli | Single protein | Burgess, W J. | Elkins, P A. | Head, M S. | Huffman, W F. | Jakas, D R. | Janson, C A. | Jr., W E.DeWolf. | Keller, P M. | Manley, P J. | Miller, W H. | Moore, T D. | Newlander, K A. | Payne, D J. | Pearson, S. | Polizzi, B J. | Qiu, X. | Rittenhouse, S F. | Seefeld, M A. | Uzinskas, I N. | Wallis, N G. | IDN | NAD | SO4 | Enoyl reductase | Enoyl-acp reductase | Fabi
